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Abstract
A systematic evaluation of three different methods for generating induced pluripotent stem (iPS) cells was performed
using the same set of parental cells in our quest to develop a feeder independent and xeno-free method for somatic
cell reprogramming that could be transferred into a GMP environment. When using the BJ fibroblast cell line, the
highest reprogramming efficiency (1.89% of starting cells) was observed with the mRNA based method which was
almost 20 fold higher than that observed with the retrovirus (0.2%) and episomal plasmid (0.10%) methods. Standard
characterisation tests did not reveal any differences in an array of pluripotency markers between the iPS lines
derived using the various methods. However, when the same methods were used to reprogram three different
primary fibroblasts lines, two derived from patients with rapid onset parkinsonism dystonia and one from an elderly
healthy volunteer, we consistently observed higher reprogramming efficiencies with the episomal plasmid method,
which was 4 fold higher when compared to the retroviral method and over 50 fold higher than the mRNA method.
Additionally, with the plasmid reprogramming protocol, recombinant vitronectin and synthemax® could be used
together with commercially available, fully defined, xeno-free essential 8 medium without significantly impacting the
reprogramming efficiency. To demonstrate the robustness of this protocol, we reprogrammed a further 2 primary
patient cell lines, one with retinosa pigmentosa and the other with Parkinsons disease. We believe that we have
optimised a simple and reproducible method which could be used as a starting point for developing GMP protocols, a
prerequisite for generating clinically relevant patient specific iPS cells.
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Introduction
Mature somatic cells can be reprogrammed to a pluripotent
state through ectopic expression of key transcription factors, in
a process known as induced pluripotency. The resulting
induced pluripotent stem (iPS) cells have unlimited proliferative
potential while maintaining the capacity to differentiate into any
cell type. These pluripotent characteristics coupled with the
ability to derive iPS cells from adult patient cells, have made
iPS cells a valuable tool for the in vitro modelling of many
human diseases, drug discovery and may potentially serve as
an unlimited source of cells for regenerative medicine. While
many patient specific iPS cell lines have already been derived,
most have been generated using genome integrating methods
which raises concerns of insertional mutagenesis and
continued expression of potentially oncogenic proteins by the
integrated transgenes [1]. These concerns are particularly
important when considering clinical translation. It is therefore
desirable to generate iPS cells using protocols that dispense
with the need for integrating viral vectors, whilst being robust
and fully compliant with good manufacturing practice (GMP)
requirements. Several integration-free methods have been
reported, including episomal plasmids [2], recombinant proteins
[3], temperature sensitive sendai virus [4], synthetic mRNA [5]
and miRNA [6] approaches, each with unique advantages and
disadvantages and reprogramming efficiencies. The initial
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report using OriP/EBNA-1 based episomal plasmids showed
that it is a technically simple method of reprogramming though,
extremely inefficient (1-3 colonies from 106 input cells) [2].
However, subsequent reports have shown that the replacement
of SV40 large T antigen, Nanog and c-Myc, with a shp53 and
L-Myc can improve reprogramming efficiencies over 10 fold [1].
These studies demonstrate that reprogramming using episomal
plasmids is a viable approach for generating integration free
iPS cells. Another interesting method of reprogramming
showed the use of a synthetic mRNA cocktail including Oct4,
Sox2, Klf4, c-Myc and Lin28 to yield reprogramming
efficiencies of up to 4.4%, the highest reported thus far [5]. The
RNA based method is not associated with chromosomal
integration, which is an important safety attribute.
However, a systematic evaluation of the reprogramming
methods is yet to be conducted using the same set of cell lines
and under the same culture conditions. Another major hurdle
for the clinical translation of iPS cells is the need to use fully
defined, xeno-free reagents. Despite progress in developing
protocols using xeno-free reagents, these methods are still
reliant on the use of human feeders and viral vectors [7-10].
Here, our aim was to compare the reprogramming efficiencies
of the retrovirus, episomal plasmid and mRNA reprogramming
methods using the same set of transformed and primary patient
cell lines to determine which method is most suitable for clinical
translation. Our data shows that the non-viral, episomal
plasmid method is most efficient and robust at reprogramming
primary human fibroblasts even under feeder free conditions
and therefore, would be most suitable for the production of
GMP grade iPS cells.
Materials and Methods
Ethics statement
All human primary fibroblast cells were generated in vitro
after written informed consent using protocols approved by the
Royal Free research ethics committee, Royal Free Hospital,
London, UK. All animal work was performed under the authority
of the UK Home Office Project and Personal Licenses
regulations and was compliant with the guidelines of the
University College London Ethics Committee.
Isolation of dermal fibroblasts and Cell culture
All reagents were sourced from Life Technologies UK, unless
otherwise stated. All cells were cultured in a humidified
incubator at 37°C in 5%CO2. Consent was obtained from
patient RDP1, 49 years old patient with rapid onset
parkinsonism dystonia (RDP); patient RDP2, 31 years old with
RDP; patient PD1, 70 years old with Parkinsons disease;
patient RP2 with retinosa pigmentosa and; control CTL1, an 81
year old healthy volunteer for tissue collection. An
approximately 3-6mm skin punch biopsy was collected by a
trained physician under local anaesthetic and fibroblasts
generated following previously published protocols [11]. BJ
fibroblast cell line (Stemgent) and established fibroblast cell
lines were cultured in fibroblast medium consisting of high
glucose DMEM (PAA cell laboratories) with 10% foetal bovine
serum, 1mM non-essential amino acids (NEAA) and penicillin-
streptomycin (PAA cell laboratories). When cells reached 80%
confluency, fibroblasts were detached using TrypLE express.
Splits of 1:3-1:5 were performed every 4-5 days with medium
being refreshed every 2-3 days. For xeno-free culture of
established fibroblast cell lines, fibroblast medium was
replaced with TheraPeak MSCGM-CD medium (Lonza). H1
hES cell line (gift of Tariq Enver, UCL Cancer Institiute, London
UK) [12] and established iPS cell lines were maintained in one
of the following combinations: irradiated newborn human
foreskin foetal fibroblasts feeders (Nuff, GlobalStem) with
hUES medium (20% knock out serum replacement in
DMEM/F12 with 1mM glutaMAX, 1mM NEAA, penicillin-
streptomycin, 0.1mM β-mercaptoethanol and 10ng/ml β-Fgf) or;
hES cell qualified matrigel (BD Biosciences) and mTESR1
(Stemcell Technologies) or; recombinant vitronectin and
essential 8 (E8) medium. Medium was refreshed every day and
cells were passaged 1:3-1:5 using collagenase type IV,
dispase (Stemcell Technologies) or gentle cell dissociation
reagent (Stemcell Technologies). Methods for passaging
human pluripotent stem cells have been described elsewhere
[13].
Reprogramming fibroblasts
Shinya Yamanaka’s pMXs-based retroviral vectors were
obtained from Addgene (Addgene numbers 17217, 17218,
17219, 17220) and have been previously described [14].
Platinum A amphotrophic packaging cell line (Cell biolabs) was
used to generate retroviruses. 105 target fibroblasts were
seeded in a single well of a 6 well plate the day prior to
transduction. The next day, viral supernatants containing equal
volume of each factor was supplemented with 8µg/ml of
polybrene (Sigma-Aldrich) and added to each well and left
overnight. Fresh retroviral supernatants were added the
following day for a second round of transduction. Four days
after the initial transduction, cells were harvested using trypLE
express and transferred to a 10cm dish seeded with 106 Nuff
feeders. The next day, medium was changed to hUES cell
medium.
Two different sets of episomal plasmids obtained from
Addgene were used in experiments. James Thomson episomal
plasmids: pEP4-EO2S-ET2K (SET2K, Addgene number
20927) and pEP4-EO2S-CK2M-EN2L (EN2L, Addgene number
20924) and Shinya Yamanaka episomal plasmids: pCXLE-
hOct3/4-shp53-F (Addgene number 27077), pCXLE-hSK
(Addgene number 27078), pCXLE-hUL (Addgene number
27080) and pCXLE-EGFP (Addgene number 27082) have
been previously described [1,2]. Early passage fibroblasts (less
than 12 passages) in growth phase were used for all
experiments. Fibroblasts were harvested with TrypLE express
and the cell pellet washed once in PBS. 106 cells were counted
and re-suspended in nucleofector solution supplied in the
Amaxa Nucleofector kit R (Lonza). Episomal plasmids were
added to the cell suspensions at various concentrations,
Thomson plasmids: SET2K 3.2µg and EN2L 7.2µg per reaction
and Yamanaka plasmids at 1µg each per reaction. Cell
suspensions were transfected using program U-023 on a
Nucleofector (I) 2b device. Immediately following transfection,
cells were re-suspended in fibroblast medium and transferred
Comparing Methods for Deriving Human iPS Cells
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to a 10cm tissue culture dish coated with 0.1% gelatine
(Sigma-Aldrich). Daily medium changes using fresh fibroblast
medium supplemented with 0.5mM sodium butyrate (Sigma-
Aldrich) was begun the following day. At day 7 post
transfection, cells were counted using trypan blue and 105
viable cells transferred to a 10cm dish seeded with 106 Nuff
feeders. Alternatively for feeder free derivation, 2×105 viable
cells were seeded into one well of a 6 well plate coated with
matrigel (BD Biosciences), recombinant vitronectin,
laminin-521 (Biolamina) or Synthemax-R (Corning). The next
day, fibroblast medium was changed to hUES cell medium,
mTESR1 or Essential 8 (E8) medium (E8 from Life
technologies or TeSR-E8 from Stemcell technologies)
supplemented with 0.5mM sodium butyrate. By day 12 post
transfection, sodium butyrate treatment was stopped and
conditioned hUES medium/mTESR1 or E8 used instead.
The mRNA reprogramming kit and Pluriton reprogramming
medium (Stemgent) were used as per manufacturer’s
instructions for both feeder dependent (Nuffs) and feeder free
(matrigel) derivation.
At day 30 post transduction/transfection, cells were either
fixed for whole plate alkaline phosphatase staining or live
stained with TRA-1-81 to pick iPS colonies. TRA-1-81 primary
antibody (Santa Cruz Technologies) was diluted 1:100 and
goat anti mouse IgG/IgM conjugated Alexa488 secondary
antibody diluted 1:400 in pre-warmed DMEM/F12. After 30
mins, plates were washed 2 times with DMEM/F12 and fresh
hUES/mTESR1/E8 medium added during imaging. The
number of TRA-1-80 positive colonies were counted and
several colonies were picked and transferred to organ well
culture dishes (BD biosciences) or 12 well plates coated with
matrigel or seeded with 104 Nuffs. After 4-5 mechanical
passages, iPS cells were switched to enzymatic passaging.
Feeder dependent iPS cell lines were transitioned and
maintained in matrigel and mTESR1 medium from passages
8-9.
Characterisation of iPS cells
Immunophenotyping entailed washing the cells once with
PBS and then fixed with 4% paraformadehyde (Electron
microscopy services) for 20 mins. Cells were washed 3 times
with PBS and then stored at 4°C in PBS. Prior to
immunostaining, cells were blocked for 30 mins with 5% goat
serum, 0.1% bovine serum albumin (Sigma-Aldrich) in PBS. If
performing nuclear staining, cells were permeabilised with ice-
cold 100% methanol for 5 mins prior to blocking. Primary
antibodies Oct3/4, TRA-1-60, SSEA-1, SSEA-3 and SSEA-4
(Santa Cruz Biotechnologies) were used at a 1:100 dilution and
used to stain cells at room temperature for one hour. Primary
antibodies were washed off 3 times with PBS and then goat
anti-mouse IgG/IgM Alexa 488 diluted 1:400 added. Secondary
antibody was incubated at room temperature for 30 mins. Cells
were washed 3 times with PBS and then DAPI (Sigma-Aldrich)
added for 5-10 mins. Cells were washed 3 times with PBS and
immediately visualised. For alkaline phosphatase staining, cells
were stained with the alkaline phosphatase staining kit
(Millipore) as per manufacturer’s instructions.
To demonstrate spontaneous in vitro differentiation, iPS cells
were grown to confluency and harvested by dispase. Cells
were re-suspended in hES medium without β-Fgf and
transferred to non-tissue culture treated 6 well plates (Grenier
Bio One). Medium was changed every 3-4 days. Day 12
embryoid bodies (EBs) were transferred to a 12 well plate
coated with 0.1% gelatine and cultured for a further 12 days in
fibroblast medium. Differentiated cells were harvested with
TRIzol and stored at -80°C until phenol chloroform RNA
extraction. 1µg of RNA was used for subsequent reverse
transcriptase reactions with Superscript III first strand synthesis
system. 1µl of cDNA was used per PCR reaction with GoTaq
green mastermix (Promega). Primers and conditions for RT-
PCR have been previously described [15].
Pluripotency and trilineage differentiation potential was also
assessed using the TaqMan® hPSC ScorecardTM kit 384w
following manufacturer’s instructions and run on a ViiA 7
system. Data analysis was performed using the cloud based
TaqMan® hPSC ScorecardTM analysis software.
Genomic DNA analysis entailed the use of the DNeasy blood
and tissue kit (Qiagen) as per manufacturer’s instructions.
100-200ng of DNA was used per PCR reaction with GoTaq
green mastermix. Primers and conditions for PCR are listed in
table 1 or have been previously described [2]. For STR
analyses, PCR products were run on a 3.5% agarose gel at
30V/cm. G-banding analysis on iPS cell colonies was
performed by either the Haematology Cellular & Molecular
Diagnostic Service, Great Ormond Street Hospital & UCL
Institute of Child Health or TDL genetics, The Doctors
laboratory, London.
For in vivo pluripotency, iPS cells were grown to confluency
and harvested by dispase. Cell pellets were re-suspended in
30% matrigel and 70% mTESR1. One confluent 6 well plate
was used per animal. 6-8 week old NOD-SCID mice were
anaesthetised by isoflurane inhalation and 50µl of the iPS cell
suspension was injected into each testis capsule. Analgesia
(Carprofen, 5mg/kg) was administered intraperitonally following
surgery to minimise pain. After 10-12 weeks, animals were
sacrificed by carbon dioxide asphyxiation and teratomas
excised and fixed in Histochoice (Amresco). Histological
processing and H&E staining were performed by either, The
Table 1. The plasmid reprogramming efficiencies of
fibroblasts cultured in xeno-free, feeder-free conditions (E8
and vitronectin).
Cell name
GFP transfection
efficiency
Number of TRA-1-81+
colonies1
Reprogramming
efficiency2
BJ control 44.02% 187±16.97 0.21%
RPD1 39.10% 113.5±13.44 0.15%
RPD2 42.52% 159.5±3.54 0.19%
PD1 45.03% 206±4.0 0.23%
RP2 42.20% 217.5±4.5 0.26%
1. n=2, mean±SE
2. reprogramming efficiency% = number of iPS colonies/number of transduced or
transfected cells.
doi: 10.1371/journal.pone.0081622.t001
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Research Department of Pathology, Faculty of Medical
Sciences, University College London or The Research
Department of Oncology, UCL Cancer Institute.
Results
Comparison of reprogramming methods using the BJ
fibroblast cell line
The standard Yamanaka retrovirus protocol was first used to
determine the baseline reprogramming efficiency of BJ
fibroblasts that could be achieved in our laboratory.
Transduction with the 4 factor retroviruses gave 112 TRA-1-81
positive iPS colonies by day 30. In parallel experiments, the
number of transduced cells was estimated to be 85.90%, as
assessed by a GFP encoding retroviral vector. (Figure S1A).
Therefore, the estimated reprogramming efficiency with
retroviral vectors was 0.2% (Figure 1A). Several retrovirus iPS
cell lines (BJ-RV-iPS) were established and one line used as a
standard for further characterisation.
Next, we compared the Thomson episomal plasmids
(encoding Oct4, Sox2, Klf4, c-Myc, Nanog, Lin28 and SV40
large T antigen) with the Yamanaka episomal plasmids
(encoding Oct4, Sox2, Lin28, L-Myc and p53 shRNA) following
their published protocols. Irradiated human neonatal foreskin
fibroblasts (Nuffs) were used as a feeder layer for both plasmid
combinations in our initial studies. The transfection efficiency of
BJ fibroblasts using the pCXLE GFP plasmid construct was
approximately 36±16% (n=4) at 24 hours after electroporation
(Figure S1B). Morphology changes in fibroblasts were
observed in induced cells with the Thomson plasmids as early
as 7 days post transfection, while for the Yamanaka plasmids,
changes were first observed at days 10-12. However, by days
25-30 more iPS-like colonies emerged from Yamanaka
plasmids. Bona fide iPS colonies were identified by TRA-1-81
live staining. An average of 43±29 colonies were observed for
Yamanaka plasmids compared with only 10.5±2.5 positive
colonies for Thomson plasmids (n=2). After taking into
consideration the transfection efficiency, the computed
reprogramming efficiency of the Yamanaka plasmid
combination was found to be over 10 fold greater
(0.012±0.008% Yamanaka vs 0.003±0.001% Thomson) at
generating iPS cells consistent with previous reports [1,16].
The Yamanaka method was, therefore, used in all subsequent
experiments. Since feeder cells can vary substantially in
quality, we sought to eliminate their use in our experiments. We
replaced the human feeders with matrigel and observed
76.33±5.6 TRA-1-81 positive colonies (n=3), which resulted in
a higher reprogramming efficiency than the feeder dependant
protocol (0.103±0.008% Yamanaka feeder free vs
0.012±0.008% Yamanaka feeder dependent). Several iPS lines
were established and one line used for further characterisation
(BJ-pla-iPS).
With the mRNA based reprogramming method, the
transfection efficiency of BJ fibroblasts with the mRNA cocktail
was highly impressive as it approached 100% as assessed
using the Axiovision software, (5 images/transfected tissue
culture wells compared with hoescht H33342 staining) (Figure
S1C). We observed early (after 3 days) morphology changes of
BJ fibroblasts from a spindle-like to a cobble stone-like
appearance and iPS cell like colonies began to emerge after 12
days of transfections, which is significantly earlier than
observed with the plasmid and retroviral reprogramming
methods. Live TRA-1-81 antibody staining of colonies at day
18, revealed 189 positive colonies, equating to a
reprogramming efficiency of 1.89%. However, when we
replaced feeders with matrigel, the reprogramming efficiency
with the mRNA protocol decreased to 0.22%. Several mRNA
derived iPS lines were established and one line was used for
further characterisation (BJ-mRNA-iPS).
The iPS lines established from BJ fibroblasts using
retrovirus, episomal plasmids and mRNA all showed typical
hES-like morphology with large nucleus to cytoplasm ratio,
highly visible nucleoli and growth as compact colonies (Figure
1A). Immuno-staining analyses indicated that all iPS lines
expressed typical hES cell antigens including alkaline
phosphatase, SSEA-3, TRA-1-60 and Oct4 (Figure 1A, 1B).
Flow cytometric analysis further demonstrated that 80-90% of
the populations expressed cell surface antigens, SSEA-4 and
TRA-1-81 but did not express SSEA-1, a mouse marker of
pluripotency, which is comparable to the hES cell profile
(Figure 1C). RT-PCR analysis showed the expression of
endogenous pluripotency genes including Oct4, Sox2, Nanog
and Rex1 in all iPS lines in contrast with the parental BJ
fibroblasts (Figure 1D). All iPS lines could be used to generate
embryoid bodies (EBs) and at day 12, EBs were transferred to
gelatine coated dishes for further spontaneous differentiation
(Figure 2A). Quantitative RT-PCR revealed the down regulation
of pluripotency genes, Oct4 and Nanog in differentiated cells
while lineage specific genes Pax6, Mixl1 and Cdx2 were up-
regulated, demonstrating the in vitro pluripotency of these cells
(Figure S2A,B). When iPS cell lines were injected into the testis
capsule of immune compromised mice, teratomas formed
which consisted of tissue derivatives indicative of the three
germ lineages confirming the in vivo pluripotency of the iPS cell
lines derived (Figure 2C). Furthermore, cytogenetic analysis
revealed normal karyotypes (Figure 2B), while DNA
fingerprinting confirmed the parental origin of iPS lines as being
derived from BJ fibroblasts (Figure S2C). Recently, Meissner’s
group reported the generation of a scorecard to predict the
pluripotency and germ layer bias of human pluripotent stem
cells [17]. We used this scorecard to compare the BJ iPS lines
generated using episomal plasmids and mRNA. Scores of 0.39
and 0.98 (scores between -0.5 and 1 are deemed the same)
were obtained for the undifferentiated iPS cells respectively,
which indicate that both lines expressed pluripotency markers
at levels comparable to the reference standard. When testing
the trilineage potential of these 2 iPS lines, day 7 embryoid
bodies were generated, analysed and found to be good general
purpose iPS cell lines without lineage bias (Figure 2D). These
scorecard results validate our results from our in vitro
differentiation and teratoma assays.
Comparison of reprogramming methods using primary
patient cell lines
Primary fibroblasts derived from two patients (RDP1 and
RDP2) and a healthy volunteer (CTL1) were derived from skin
Comparing Methods for Deriving Human iPS Cells
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Figure 1.  Characterisation of established iPS lines derived from BJ fibroblasts using retrovirus, plasmids and mRNA.  A)
Representative phase images of established iPS and H1 cell lines. Immunostaining with pluripotency markers (green) and counter
staining with DAPI (blue). Scale bar is 200µm. B) Alkaline phosphatase staining of whole plates/wells at days 30 (retrovirus and
plasmid) and day 20 (mRNA). C) Flow cytometry analysis with pluripotency markers SSEA-4 and TRA-1-81. SSEA-1 is a negative
marker of human pluripotent stem cells. Green line denotes H1, red line denotes BJ-RV-iPS, green line denotes BJ-Pla-iPS and
black line denotes BJ-mRNA-iPS. D) RT-PCR analysis for expression of key pluripotency genes.
doi: 10.1371/journal.pone.0081622.g001
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Figure 2.  Pluripotency of established iPS lines and detecting the genomic integration of episomal plasmids.  A)
Representative images of embryoid bodies (EBs) generated from BJ-pla-iPS (left) and BJ-mRNA-iPS (right). B) Repsentative image
of karyotype 46, XY. BJ-pla-iPS cells at passage 15 is shown. C) H&E stained slides of teratomas formed from injections of iPS
cells into the testis capsule of NOD-SCID mice. Tissue derivatives indicative of the three germ lineages were observed. D) Human
pluripotent stem cell scorecard assay results comparing BJ-pla-iPS and BJ-mRNA-iPS lines.
doi: 10.1371/journal.pone.0081622.g002
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biopsy samples obtained following informed consent. All 3 lines
could be readily transduced with retroviral vectors, with GFP
efficiencies of > 90% (Figure S1A). The number of TRA-1-81
positive iPS colonies observed with the retroviral method for
RDP1 was 49, RDP2 was 31 and CTL1 was 12. Taking into
consideration the GFP transduction efficiencies, the computed
reprogramming efficiencies were 0.06%, 0.04% and 0.02%
respectively. Using the Yamanaka episomal plasmid method
under feeder free conditions, patient iPS lines were generated
at efficiencies equal to or greater than that seen when
reprogramming with retrovirus. RDP1 (0.09±0.02%) and RDP2
(0.16±0.06%) were more efficiently reprogrammed than CTL1
(0.02±0.0003%). These differences in reprogramming
efficiency did not appear to be related to disease status but
suggested a correlation with the age of the patient as reported
before [18,19]. In contrast, attempts to reprogram RDP1 and
RDP2 cell lines on 5 separate occasions with the mRNA
method was largely unsuccessful even though parallel control
studies with the BJ fibroblast cell line consistently showed a
high reprogramming efficacy. Several variations of this protocol
were attempted including different fibroblast seeding densities
(ranging from 104to 105), hypoxia (5% O2) and the addition of a
Stemgent proprietary microRNA cocktail. Three TRA-1-81
positive iPS-like colonies emerged from RDP2 cells after 25
days in culture using conditions in which the mRNA cocktail
was combined with microRNA but not with the other conditions.
Unfortunately, these 3 colonies could not be expanded into
stable iPS lines as they began differentiating after the first
passage.
The patient specific iPS lines derived using plasmids in
feeder free conditions were characterized using the standard
pluripotency assays. These patient iPS lines expressed key
markers of pluripotency as determined by RT-PCR and
immunostaining, and formed teratomas when injected into
SCID mice (Figure 3A-C). All patient iPS lines had normal
karyotypes, despite extensive passaging (Figure 3D). DNA
fingerprinting confirmed their paternity (Figure S2C). Most
importantly, genomic PCR analyses which can detect the
EBNA-1 and OriP sequences with a sensitivity of 1 copy in 105
cells showed that these plasmid sequences could not be found
in iPS lines from passage 10 onwards (Figure 4A). This
indicates that all the iPS lines generated using plasmids (BJ-
pla-iPS, RDP1-iPS, RDP2-iPS and CTL1-iPS) were indeed
integration-free.
Using a xeno-free method for generating patient iPS
cell lines
To bring iPS cells a step closer to the clinic, protocols for
generating patient iPS cells ideally need to be feeder free,
integration free and derived using fully defined xeno-free
reagents. As the episomal plasmid method for iPS cell
derivation was the most efficient and robust when
reprogramming primary patient fibroblasts, we attempted to
optimise this protocol further to achieve a method that could be
amenable to GMP processes. We first replaced matrigel with
laminin-521 but failed to generate any iPS cell colonies (data
not shown). Next, we used recombinant vitronectin and
Synthemax®, a novel vitronectin-mimicking surface and both
allowed robust generation of RDP2 specific iPS colonies at
efficiencies (0.18±0.03% and 0.27±0.06% respectively)
comparable to matrigel (0.15±0.05%, n=3) [16-18]. To eliminate
the use of mTESR1 medium which contains bovine serum
albumin, we adopted the xeno-free essential 8 (E8) medium
and recombinant vitronectin system developed by the Thomson
lab [20] and observed an improved reprogramming efficiency of
0.23±0.08% (n=3) using RDP2 fibroblasts but this was not
significant compared with mTESR1/matrigel system. To
demonstrate the robustness of our feeder-free plasmid protocol
using Thomson’s E8/vitronectin culture conditions, we further
reprogrammed 3 more primary patient cell lines: RPD1, PD1
and RP2 all at high efficiencies (see Table 1 and Fig 4D).
Several patient (RP2) iPS lines derived in these conditions
were picked and continually expanded in E8 medium and either
vitronectin, Synthemax® or matrigel matrices. Patient iPS cells
expanded in vitronectin and Synthemax® appeared to be more
flattened with less defined, rounded borders compared with iPS
cells cultured in matrigel which matched previous observations
(Fig 4B) [20]. To determine whether the morphology
differences observed between vitronectin, Synthemax® and
matrigel also led to differences in the expression of key
markers of pluripotency, flow cytometry analysis was
performed. The percentage of SSEA-4, TRA-1-60 and
TRA-1-81 surface antigens expressed on iPS lines derived and
maintained in matrigel was higher than with vitronectin and
Synthemax®, but this was not statistically significant (Fig 4C).
While the morphology of iPS colonies grown in vitronectin and
synthemax® is distinct, our results show that these two
matrices have the capacity to support both plasmid
reprogramming and the growth of pluripotent stem cells which
is consistent with previous findings [20]. In a step to further
make our protocol more amenable to GMP processes, we
eliminated FBS present in our fibroblast medium by using
MSCGM-CD medium, a GMP qualified medium. Using
MSCGM-CD medium combined with sodium butyrate during
the first 7 days of the reprogramming process subsequently
followed by culture on recombinant vitronectin and in E8
medium, we could also reprogram cells from patient RP2 at
efficiencies equivalent to that observed when using foetal calf
serum based medium (results not shown).
Discussion
Since Takahashi and Yamanaka’s landmark study, there
have been an exponential number of publications describing
the generation of iPS cells. While iPS cells can now be
generated routinely in most stem cell laboratories, there is still
no consensus on the best method to move forward with in a
clinical setting. This question must be answered quickly so that
we can turn our attention towards deriving the first GMP grade
iPS cell lines. Currently, there are several limitations to the use
of iPS cell derived progenitors in the clinic. Firstly, the use of
genome integrating viruses needs to be eliminated to decrease
the risk of oncogenesis. Secondly, the iPS cells must be
generated using fully defined xeno-free reagents to comply with
GMP requirements. In this study we performed a side-by-side
comparison of the most clinically relevant reprogramming
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Figure 3.  Characterisation of established patient specific iPS lines.  A) Phase images of iPS lines established from patients
RDP1, RDP2 and CTL1 using episomal plasmids. Immunostaining for markers of pluripotency shown in green. Cells were counter
stained with DAPI (blue). Scale bar is 200µm. B) RT-PCR analysis showing expression of endogenous pluripotency genes: Oct4,
Sox2, Nanog and Rex-1. C) Representative slides showing H&E staining of teratomas formed from injection of patient iPS lines into
NOD SCID mice. Tissue derivatives indicative of the three germ lineages are shown. D). Representative karyotype, 46 XY of CTL1-
iPS line analysed at passage 42.
doi: 10.1371/journal.pone.0081622.g003
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Figure 4.  Comparison of different culture conditions during plasmid based reprogramming.  A) Genomic integration of
episomal plasmids. EBNA-1 and OriP sequences could not be detected in established iPS lines by passage 10. B) Morphology of
RDP2-iPS cell lines derived in E8 medium, using different extracellular matrices. Scale bar is 400µm. C) Flow cytometric analysis of
SSEA-4, TRA-1-81 and TRA-1-60 expression in RDP2-iPS cell lines derived on different matrices. Grey shaded areas denote the
secondary antibody alone control. D) Whole well alkaline phosphatase staining of BJ, RDP2, PD1 and RP2 fibroblasts at day 30 of
reprogramming using E8 medium and vitronectin.
doi: 10.1371/journal.pone.0081622.g004
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methods to identify one that is most suitable for the generation
of iPS cells using GMP conditions. Our studies show that the
Yamanaka plasmid based method is as efficient as the
standard retroviral method at reprogramming an established
cell line like BJ fibroblasts as well as primary fibroblasts derived
from patients with a neurodegenerative condition or an elderly
healthy volunteer. Importantly, the plasmid vectors were not
detectable in the reprogrammed iPS cells consistent with the
fact that they are maintained episomally, which is an important
safety advantage. In addition, plasmid vectors can be
manufactured and qualified for GMP use at a fraction of the
cost of Sendai viral vectors.
On the other hand, the mRNA reprogramming method offers
the advantage of being completely free of genomic integration
and is therefore highly suitable for clinical translation. However,
the mRNA method was very inefficient at reprogramming
primary patient fibroblasts consistent with the experience of
several groups [21-23]. Therefore, further optimisation of this
method is clearly required. Indeed our studies suggested that
the inclusion of microRNA in the reprogramming cocktail did
improve the reprogramming frequency of primary fibroblasts.
Another disadvantage of the RNA based reprogramming
method is that it is highly demanding, requiring daily
transfections for 12 days, thus making it more difficult to
develop a GMP compliant process.
Although we found differences in reprogramming efficiencies
between the plasmid and mRNA methodologies, we did not
observe any qualitative differences in the iPS cell lines derived.
The established iPS lines were compared using standard tests
of pluripotency: expression of pluripotency markers using PCR
and antibody staining, in vitro differentiation and in vivo
differentiation potential through teratoma formation. In fact, all
the iPS lines behaved similarly to the hES cell line, H1. We
also compared our plasmid and mRNA derived iPS lines using
the human pluripotent stem cell scorecard described by
Meissner’s group [17]. This scorecard compares the gene
expression pattern of key pluripotency and germ lineage
markers relative to a reference standard that consists of 9
different human ES and iPS lines. Using cloud based software,
we showed that our iPS lines derived using plasmids and
mRNA were comparable to the reference standard and did not
show any lineage bias. Indeed, the scorecard results confirmed
our in vitro differentiation and teratoma assay results,
suggesting that this focused array could potentially replace the
more traditional tests of pluripotency. However, more partially
and fully reprogrammed iPS lines will need to be fully analysed
using the scorecard to demonstrate its efficacy.
Our findings show that there are no differences between iPS
lines derived using plasmids and mRNA which supports a
recent study comparing the hepatic differentiation potential of
several iPS cell lines derived from different patients using
episomal plasmids, Sendai virus or retrovirus, and showed that
the major determinant of hepatic differentiation potential was
the genetic background of patients and not the method of
reprogramming [16]. While another study, showed that iPS
lines generated from 5 different methods (3 factor vs 4 factor
retroviral, lentiviral, episomal plasmid and mRNA) all acquired
genetic mutations at the same frequency which was thought to
be a consequence of extensive time in culture rather than the
reprogramming method itself [24]. Taken together, these
studies and our own suggest that the reprogramming method
does not affect the quality of iPS cell lines produced.
Given the robustness of plasmid based reprogramming, we
optimised this method further and showed that iPS cells can be
derived using xeno-free ECMs and with defined media that is
free of xeno-proteins without significant change in the
reprogramming frequency. We achieved this by capitalising on
the findings of two previous reports where one had
demonstrated the generation of plasmid derived iPS lines in
feeder free conditions using a complex cocktail of MEK-,
GSK-3-, ROCK- and TGFβ- inhibitors while the other report
showed that sodium butyrate improved the reprogramming
efficiency of blood mononuclear cells (MNCs), though requiring
the presence of feeders [25,26]. In contrast to other groups, we
did not notice a significant decline in reprogramming efficiency
with our feeder free protocol when compared to the feeder
dependent method [27]. In addition, in our hands the plasmid
method was very reproducible and capable of reprogramming
primary fibroblasts from 5 different donors of varying ages
(31-81 years old). All the patient iPS lines derived using
plasmids possessed characteristics indicative of human
pluripotent stem cells. This is consistent with what has been
reported previously in the literature where a range of cell types
including neonatal fibroblasts, dental pulp cells, adipose cells,
CD34+ cells from cord blood and peripheral blood that have
been successfully reprogrammed with this method [1,25,26].
While Karumbayaram et al. have reported the generation of
patient iPS cells from skin biopsy using STEMCCA lentivirus
and eventual differentiation into neurons under GMP compliant
conditions, we are the first to show the generation of patient
specific iPS cells using a non-viral method under feeder free
conditions and with xeno-free reagents which can be easily
transferred to a clean room environment with full GMP
compliancy [10].
During the preparation of this manuscript, two ground
breaking reports were published which could have major
implications for iPS cell technology. The first report by Hou and
colleagues showed that mouse iPS cells could be generated
using a chemical cocktail of seven small compounds in 2i
culture conditions without the addition of exogenous factors
[28]. Small molecules are an attractive method of
reprogramming, as their timing and delivery can be easily
controlled by adjusting their concentrations in the culture
medium. Although the caveat is that small molecules could
elicit unknown off target effects, which may be no less
detrimental than the transient expression of exogenous factors.
In a different report, Jacob Hanna’s group achieved near 100%
efficiency when generating mouse iPS cells from several
different somatic cell types by eliminating the expression of the
methyl-binding protein 3 (Mbd3), a key component of the
nucleosome remodelling and deacetylation repressor complex
(NuRD) [29]. However, such high efficiencies were only
obtained in ‘secondary reprogrammable’ Mbd3 knock out
somatic cells while siRNA knockdown of Mbd3 in wild type
mouse embryonic fibroblasts only resulted in efficiencies of up
to 18% [29]. While Mbd3 has been previously shown to be a
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roadblock to reprogramming, these findings are novel in that
they support the notion of reprogramming being a deterministic
process and not stochastic [30]. These studies clearly
demonstrate that epigenetic modifiers are important for
reprogramming and might be the key to finally establishing
human iPS cells that are in the ground state of pluripotency.
Further studies are needed to determine whether Mbd3 and
other epigenetic modifiers serve to simply increase the
efficiency of iPS cell generation or whether higher quality iPS
cells can be generated with their use.
Conclusions
This study is the first systematic evaluation of 3
reprogramming methodologies using the same set of cell lines
and culture conditions which showed that episomal plasmids
were the most suitable for developing a GMP compliant
method for reprogramming primary patient fibroblasts. The
robustness of our protocol was demonstrated by the high
efficiency generation of 5 integration free and feeder free,
patient specific iPS cell lines. We believe our protocol can be
easily transferred to a clean room environment and hope that
this will constitute a first step towards the derivation of GMP
grade human iPS cell lines.
Supporting Information
Figure S1.  Transduction and transfection efficiencies of
fibroblasts. A) GFP retroviral transduction of fibroblast cell
lines. Scale bar on images is 200µm. Flow cytometric profiles
show percentage of cells that are GFP positive. B) GFP
transfection efficiency of fibroblast cell lines using the episomal
plasmid. Scale bar on images is 200µm. Flow cytometric
profiles show percentage of cells that are GFP positive. C)
Overlay and individual Axiovision images of BJ fibroblasts
transfected with GFP mRNA and counter stained with hoescht
H33342.
(TIF)
Figure S2.  Q-PCR of embryoid bodies (EBs) and DNA
fingerprinting. A) Q-PCR showing the down regulation of
pluripotency genes, Oct4 and Nanog in differentiated (diff) EBs
relative to iPS lines. All results were normalised to the GAPDH
housekeeping gene. B) Q-PCR showing the up regulation of
lineage specific genes: Cdx2 (mesoderm), Mixl (mesendoderm)
and Pax6 (ectoderm) in EBs relative to iPS lines. All results
were normalised to the GAPDH housekeeping gene. C) DNA
fingerprinting of iPS lines and starting parental fibroblasts, 3
loci are shown.
(TIF)
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